Merz acquires Cuvposa

GREENSBORO, N.C. — Merz announced it has acquired a medication designed to treat a condition associated with such neurologic conditions as cerebral palsy.

The company said it acquired Cuvposa (glycopyrrolate) oral solution from drug maker Shionogi. Cuvposa, which has been commercially available since April 2011, is the only Food and Drug Administration-approved treatment to reduce chronic severe drooling — a condition known as sialorrhea — in pediatric patients ages 3 to 16 years with neurologic conditions associated with problem drooling, such as cerebral palsy.

"The acquisition of Cuvposa is a promising addition to our neurology business and reflects our commitment to becoming a recognized leader in the treatment of movement disorders and related conditions in the U.S.," Merz president and CEO Bill Humphries said. "Globally, the Merz Pharma Group is deeply committed to offering novel therapeutic options that address the large unmet medical needs that exists within the areas of central nervous system and neurology."

Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.